PGNY Progyny, Inc.
$30.10+3.58%
Last close: · regular session · Last 60 sessions
After-hours $30.17 +0.23% ·
- Float
- 68.6M
- Last filing
- 8-K · Nov 4, 2026
Latest SEC filings for PGNY
| 8-K | Current report | |
| 4 | Insider transaction | |
| 144 | ||
| 10-Q | Quarterly report | |
| SCHEDULE 13G/A | ||
| 8-K | Current report | |
| SCHEDULE 13G/A | ||
| 8-K | Current report | |
| 8-K | Current report | |
| 10-Q | Quarterly report |
Dilution today: new offering filings and reverse splits
Float: 68.6M shares. Latest SEC filing: 8-K on Nov 4, 2026. PGNY closed at $30.10 (+3.58%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for PGNY in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Medical - Healthcare Information Services
- Country: US
- Exchange: NASDAQ
- Employees: 675
- Website: https://www.progyny.com
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest PGNY news
- Progyny raises 2026 revenue outlook to $1.365B-$1.385B as it adds 1.3 million new covered lives Read article
- Progyny Non-GAAP EPS of $0.52 beats by $0.01, revenue of $341.2M beats by $0.44M Read article
- Progyny (PGNY) Soars 6.3%: Is Further Upside Left in the Stock? Read article
- PGNY or CRL: Which Is the Better Value Stock Right Now? Read article
- Progyny, Inc. Selling Season Pacing to Record Level, Revealing Critical Insights on Latest Market Dynamics Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.